Biogen Inc vs TORM plc — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while TORM plc trades at $28.33 (market cap $2.93B). The key difference: Biogen Inc is far larger — about 10.3× TORM plc's market cap, and TORM plc pays a 9.77% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | TRMD | |
|---|---|---|
Market Cap | $30.13B | $2.93B |
Sector | Health | Technology |
52-Week High | $216.63 | $34.87 |
52-Week Low | $128.93 | $18.77 |
Enterprise Value | $37.20B | $3.82B |
Dividend Yield | — | 9.77% |
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →